Patients treated with chemotherapy or immunosuppressives are at higher risk of influenza infection and mortality and morbidity are higher compared to healthy adults. Vaccination against the influenza virus can prevent these complications. In this study it is investigated whether vaccination during chemotherapy is effective in reaching protective serum antibody concentrations and the relation between time of vaccination (day 4 +/- 1 day versus day 16 +/- 1 day of the chemotherapy cycle).

开始日期2009-10-01

申办/合作机构

St.-Antonius-Hospital gGmbH

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的专利（医药）

登录后查看更多信息

项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的文献（医药）

2024-12-31·Human Vaccines & Immunotherapeutics

Inactivated influenza virus vaccines expressing COBRA hemagglutinin elicited broadly reactive, long-lived protective antibodies

Article

作者: Shi, Hua ; Freiden, Pam ; Zhang, Xiaojian ; Ross, Ted M ; Livingston, Brandi ; Schultz-Cherry, Stacey ; Meliopoulos, Victoria ; Ge, Pan

The influenza viruses cause seasonal respiratory illness that affect millions of people globally every year. Prophylactic vaccines are the recommended method to prevent the breakout of influenza epidemics. One of the current commercial influenza vaccines consists of inactivated viruses that are selected months prior to the start of a new influenza season. In many seasons, the vaccine effectiveness (VE) of these vaccines can be relatively low. Therefore, there is an urgent need to develop an improved, more universal influenza vaccine (UIV) that can provide broad protection against various drifted strains in all age groups. To meet this need, the computationally optimized broadly reactive antigen (COBRA) methodology was developed to design a hemagglutinin (HA) molecule as a new influenza vaccine. In this study, COBRA HA-based inactivated influenza viruses (IIV) expressing the COBRA HA from H1 or H3 influenza viruses were developed and characterized for the elicitation of immediate and long-term protective immunity in both immunologically naïve or influenza pre-immune animal models. These results were compared to animals vaccinated with IIV vaccines expressing wild-type H1 or H3 HA proteins (WT-IIV). The COBRA-IIV elicited long-lasting broadly reactive antibodies that had hemagglutination-inhibition (HAI) activity against drifted influenza variants.

2024-10-01·Vaccine

Enhancing NA immunogenicity through novel VLP designs.

Article

作者: Mesurado, Tomas ; Guzman Ruiz, Leticia ; Zollner, Alexander M ; Pereira Aguilar, Patricia ; Klausberger, Miriam ; Jungbauer, Alois ; Hausjell, Christina ; Hoxie, Irene ; Grabherr, Reingard ; Küchler, Jan ; Krammer, Florian

Current influenza virus vaccines poorly display key neuraminidase (NA) epitopes and do not robustly induce NA-reactive antibodies; instead, they focus on the induction of hemagglutinin (HA)-reactive antibodies. Next-generation influenza vaccines should be optimized in order to activate NA-reactive B cells and to induce a broadly cross-reactive and protective antibody response. We aimed at enhancing the immunogenicity of the NA on vaccines by two strategies: (i) modifying the HA:NA ratio of the vaccine preparation and (ii) exposing epitopes on the lateral surface or beneath the head of the NA by extending the NA stalk. The H1N1 glycoproteins from the influenza virus A/California/04/2009 strain were displayed on human immunodeficiency virus 1 (HIV-1) gag-based virus-like particles (VLP). Using the baculovirus insect cell expression system, we biased the quantity of surface glycoproteins employing two different promoters, the very late baculovirus p10 promoter and the early and late gp64 promoter. This led to a 1:1 to 2:1 HA:NA ratio, which was approximately double or triple the amount of NA as present on the wild-type influenza A virus (HA:NA ratio 3:1 to 5:1). Furthermore, by insertion of 15 amino acids from the A-New York/61/2012 strain (NY12) which prolongates the NA stalk (NA long stalk; NA-LS), we intended to improve the accessibility of the NA. Six different types of VLPs were produced and purified using a platform downstream process based on Capto-Core 700™ followed by Capto-Heparin™ affinity chromatography combined with ultracentrifugation. These VLPs were then tested in a mouse model. Robust titers of antibodies that inhibit the neuraminidase activity were elicited even after vaccination with two low doses (0.3 μg) of the H1N1 VLPs without compromising the anti-HA responses. In conclusion, our results demonstrate the feasibility of the two developed strategies to retain HA immunogenicity and improve NA immunogenicity as a future influenza vaccine candidate.

2024-10-01·International Journal of Infectious Diseases

Vaccine-related influenza virus B infection in a child with an undiagnosed B-cell acute lymphoblastic leukemia

Article

作者: Biffi, Alessandra ; Conciatori, Valeria ; Salata, Cristiano ; Franchin, Elisa ; Sopra, Sarah Di ; Lavezzo, Enrico ; Vecchio, Claudia Del ; Pietra, Giuseppe Di ; Castagliuolo, Ignazio ; Petris, Maria Grazia

We report a case of Influenza type B (lineage Yamagata) infection in a child who received the live attenuated influenza virus vaccine before being diagnosed with B-cell acute lymphoblastic leukemia. The patient developed a mild disease that persisted for 18 days and resolved without antiviral treatment. The prolonged infection of an attenuated virus in an immunocompromised host might pose a risk of reversion or evolution to a more pathogenic strain. Prompt prevention, identification, and monitoring of similar cases are desirable to avoid the development of severe illness, which could complicate patient management.

100 项与 Influenza virus vaccine(Crucell Holdings, Inc.) 相关的药物交易

登录后查看更多信息